Business Context and Reporting Period
Company: Aethlon Medical, Inc. (AEMD)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three months ended June 30, 2009
Business Overview: Aethlon is a development-stage medical device company focused on the Hemopurifier(R) platform, designed to remove viruses and toxins from human blood. The company has not generated revenue from principal operations and is seeking FDA approval to initiate clinical trials for treating HIV, Hepatitis-C, and potential biological warfare agents.
Key Financial Metrics
| Metric | Q2 2009 | Q2 2008 |
|---|---|---|
| Revenues | $0 | $0 |
| Operating Expenses | $641,955 | $623,659 |
| Net Loss | $(995,939) | $(998,815) |
| Loss Per Share (Basic/Diluted) | $(0.02) | $(0.03) |
| Cash and Equivalents (End of Period) | $90,317 | $156,904 |
| Net Cash Used in Operating Activities | $(366,040) | $(597,787) |
| Net Cash Provided by Financing Activities | $450,200 | $500,000 |
| Total Current Liabilities | $4,016,201 | N/A |
| Working Capital | $(3,873,204) | N/A |
Note: The company reported a derivative liability of $316,635 as of June 30, 2009, which did not exist in the prior period due to new accounting standards (EITF 07-5).
Material Changes vs. Prior Period
- Operating Expenses: Increased by $18,296 (3%) primarily due to a $75,578 rise in professional fees (driven by investor relations and business development consulting), partially offset by decreases in payroll and general administrative expenses.
- Interest Expense: Decreased significantly by $246,191 to $316,657. This reduction was largely due to the amortization of note discounts, as most discounts were fully amortized by March 31, 2009.
- Derivative Liability: A new expense of $37,434 was recorded for the change in fair value of a derivative liability, whereas the prior year included a gain of $187,692 on similar items.
- Liquidity: Cash increased by $84,160 during the quarter to $90,317, funded primarily by $450,200 in financing activities (issuance of convertible notes and common stock).
Outlook, Risks, and Management Commentary
- Going Concern: The filing explicitly states that the company's financial condition raises significant doubt about its ability to continue as a going concern. The company has a stockholders' deficit of approximately $3.7 million and negative working capital of approximately $3.9 million.
- Capital Needs: Management estimates a minimum requirement of $150,000 per month to sustain operations. Additional capital is required to fund R&D, clinical trials, and regulatory approvals.
- Debt Defaults: As of June 30, 2009, various promissory and convertible notes totaling $1,219,500 in principal are past due and in default. Accrued interest on these notes totaled $381,983.
- Regulatory Status: The company has filed an Investigational Device Exemption (IDE) with the FDA to proceed with human safety studies. Commercialization is contingent upon successful clinical trials and FDA approval, which could take years.
- Internal Controls: Management identified material weaknesses in internal controls over financial reporting, specifically regarding segregation of duties in cash disbursements and a lack of sufficient accounting personnel.
Investor Verification Checklist
- Debt Maturity: Verify the status of the $1.2 million in past-due notes and the company's ability to refinance or convert them to equity.
- Cash Runway: Assess if the $90,317 cash balance and recent $330,000 convertible note (issued in July 2009) are sufficient to meet the stated $150,000 monthly burn rate.
- Dilution Risk: Review the terms of recent convertible notes and warrants, which include "down-round" protection and low conversion prices ($0.15-$0.25), posing significant dilution risk to existing shareholders.
- Regulatory Milestones: Monitor the status of the FDA IDE and the timeline for initiating human clinical trials.
- Going Concern Status: Confirm if the company has secured the additional financing necessary to avoid insolvency in the near term.